Polish public radio covers fresh results for amycretin, the next Novo Nordisk weight loss candidate after Wegovy and CagriSema.
Recap by typeshit. Full story at www.polskieradio.pl.
Researchers are starting to explain the shifts in libido some GLP-1 users report. The full story covers what scientists have found so far.
Bikman says the added glucagon receptor push raises energy use and liver fat burning, and points to 24.2% weight loss on 12 mg in phase 2.
9:08
Archibald takes on a common question about low retatrutide doses and the drug's glucagon action. His view, not settled science, and retatrutide is still unapproved.
A report says an Eli Lilly drug helped protect muscle mass when combined with Novo's Wegovy, addressing a common worry about lean mass loss.
A new paper presents a computational pipeline for designing peptide binders, aiming to fix cases where deep learning confidence scores mislead.
Alessandro Sette's lab will track T cell responses in people before and after starting GLP-1s, including to Parkinson's-linked proteins. He is enrolling himself too.
Loading…